Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
October 2025
Secukinumab in active lupus nephritis: Results from Phase III, randomised, placebo controlled study (SELUNE) and open-label extension study
Rheumatology 2025 Doi: 10.1093/rheumatology/keaf536 Epub ahead of print
Secukinumab did not demonstrate superior efficacy over PBO in patients with active LN; secukinumab was well-tolerated with no new or unexpected safety signals detected. A Phase-III core study (SELUNE) and an extension study, were conducted by Zhao et al. to evaluate the efficacy and safety of SC secukinumab 300mg compared with PBO, in combination with the SoC, in patients with active LN.
August 2023
Effect of Belimumab on Kidney-related Outcomes in Patients with Lupus Nephritis: Post Hoc Subgroup Analyses of the Phase 3 BLISS-LN Trial
Nephrol Dial Transplant. 2023;38(12):2733–42 doi: 10.1093/ndt/gfad167 Epub ahead of print.
These data highlight the consistent benefit of belimumab versus placebo, combined with standard therapy, on kidney outcomes in both newly diagnosed and relapsed patients, and regardless of the use of GC pulses at induction.